View Older Stories
-
FDA approves GSK lung cancer drug Jideytro ahead of schedule
-
GSK halts camlipixant development for chronic cough after mixed results
-
GSK terminates collaboration with Alector after trial failures
-
HSBC Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Hold
-
Increasing unusual put option volume: MDLN GSK KVYO BIRK CPRT CIA APD CTSH DT SWKS
-
FDA approves GSK and Spero's oral carbapenem antibiotic Utebzi
-
GSK receives FDA approval for oral antibiotic to treat UTIs
-
German government to drop variable drug discounting plans - Reuters
-
Nuvation Bio (NUVB) Reiterated at Market Outperform by Citizens Amid Acquisition by GSK
-
GSK (GSK) call put ratio 1 call to 3.5 with a focus on June 50 puts active
-
GSK (GSK) In Talks To Buy Biotech Nuvalent For More Than $9 bln- FT
-
Kepler Cheuvreux Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Buy
-
This European pharma company's next three months are catalyst-rich: Bernstein
-
Increasing unusual call option volume: KOPN ERAS OGN FEZ VAL SANM GSK RMBS
-
GlaxoSmithKline (GSK) Reports Q1 EPS of GBP0.47
-
GSK (GSK) spreader of 18K contracts of May 56 calls, 12K contracts of May 60 calls and 12K contracts of May 51 puts
-
GSK (GSK) spreader of 18K contracts of May 56 calls, 12K contracts of May 60 calls and 12K contracts of May 51 puts
-
GSK nixes application for drug touted by Trump for autism - WSJ
-
GSK wins FDA approval for first drug treating liver disease itch
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
FDA expands GSK's AREXVY vaccine approval to adults 18-49 at risk
-
Morgan Stanley Reiterates Underweight Rating on GlaxoSmithKline (GSK:LN) (GSK): "risk/reward skewed to downside"
-
GSK and Bora Pharmaceuticals renew $250M five-year manufacturing deal
-
Increasing unusual call option volume: BGS IGV GPRE ZSL AXTI CARR SIRI RPRX GSK VEEV NTRA TRX STM HP
-
Increasing unusual call option volume: CNK JBS IGV EMBJ VRNS NVT GTM ZSL GSK
-
GSK preview – likely to guide modest FY26 growth betting on vaccines and specialty drugs
-
Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'
-
Wells Fargo Downgrades Rapt Therapeutics (RAPT) to Equal Weight
-
Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
-
Clear Street Downgrades Rapt Therapeutics (RAPT) to Hold
-
GSK to acquire RAPT Therapeutics for $2.2 billion in food allergy deal
-
Shionogi Invests $2.1 bln To Raise Stake in Viiv Healthcare - Bloomberg
-
Summit Therapeutics partners with GSK for cancer drug combination trial
-
GSK (GSK) call put ratio 3.2 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Barclays Downgrades GlaxoSmithKline (GSK) to Underweight
-
GSK receives Japan approval for asthma and nasal polyp treatment
-
GSK wins China approval for Nucala COPD treatment
-
Drugmakers Raise Us Prices On 350 Medicines Despite Pressure From Trump - Reuters
-
Samsung Biologics to buy GSK's Maryland facility for $280 million
-
14 of 17 Leading Drug Manufactures Now Part of Trump Most Favored Nation Efforts
-
At Least 7 Drug Companies to Announce Price Cuts with Trump at White House - WaPo
-
FDA approves GSK's Exdensur for severe asthma treatment
-
GSK terminates collaboration agreement with IDEAYA Biosciences
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
AnaptysBio files lawsuit against Tesaro and GSK over license deal
-
Bernstein on IRA pricing: $245 really is the floor
-
BofA Securities Upgrades GlaxoSmithKline (GSK) to Neutral
-
BofA Securities Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Neutral
-
CFRA Upgrades GlaxoSmithKline (GSK) to Buy
-
FDA approves GSK's Blenrep for relapsed multiple myeloma treatment
